Formulation and Optimization of Polymeric Nanoparticles for Intranasal Delivery of Lorazepam Using Box-Behnken Design: In Vitro and In Vivo Evaluation
Figure 12
(a) -Lorazepam concentration in rat blood at different time intervals following LS (i.v.), LS (i.n.), and Lzp-PLGA-NPs (i.n.) administration. (b) -Lorazepam concentration in rat brain at different time intervals following LS (i.v.), LS (i.n.), and lorazepam NPs (i.n.) administration.
